9,103 Results

Dermavant Sciences acquires rights to tapinarof from GSK. This is an investigational therapeutic aryl hydrocarbon receptor modulating agent for the treatment of psoriasis and atopic dermatitis.

 Added ago

GSK has announced that Dermavant Sciences, a subsidiary of Roivant Sciences, has agreed to purchase the rights to tapinarof, an...

Baloxavir marboxil success in Phase III CAPSTONE-2 study to treat influenza.- Genentech/Roche + Shionogi.

 Added ago

Genentech, announced that the Phase III CAPSTONE-2 study assessing the safety and efficacy of baloxavir marboxil in people at high...

Idera Pharma and BioCryst merger is terminated.

 Added 1 day ago

Idera Pharmaceuticals, Inc.announced that the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) entered into by and among...

Enzyvant initiated its rolling submission to the FDA of a BLA for RVT 802 to treat complete DiGeorge Anomaly effects.

 Added 1 day ago

Enzyvant, has initiated its rolling submission of a Biologics License Application (BLA) for RVT 802 to the FDA. The company...

FDA approves Xtandi for non-metastatic prostate cancer.- Astellas + Pfizer.

 Added 2 days ago

Astellas Pharma and Pfizer announced the FDA approved a supplemental New Drug Application (sNDA) for Xtandi (enzalutamide), following FDA Priority...

FDA approves expanding indication of the Elecsys BRAHMS PCT assay to aid antibiotic treatment in infection.- Roche.

 Added 2 days ago

Roche announced that it has received clearance from the FDA for the expanded use of its Elecsys BRAHMS PCT assay...

FDA advisory committee recommends approval of Krintafel for malaria.- GlaxoSmithKline.

 Added 2 days ago

The Antimicrobial Drugs Advisory Committee (AMDAC) of the FDA voted that there is substantial evidence of the effectiveness (13 for;...

FDA approves Tpoxx for smallpox.- SIGA Technologies.

 Added 2 days ago

The FDA has approved Tpoxx (tecovirimat), from SIGA Technologies, as the first drug with an indication for treatment of smallpox....

Sight Diagnostics received a CE mark for its point-of-care blood diagnostic device, OLO.

 Added 3 days ago

Sight Diagnostics received a CE mark for its point-of-care blood diagnostic device, OLO, which uses artificial intelligence to optically read...

Patent appeal positive for Gilenya extending exclusivity to 2027. - Novartis.

 Added 3 days ago

Novartis has successfully defeated an inter partes review challenge to a key patent for its multiple sclerosis drug Gilenya. An...

Load more